JP2008543926A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543926A5
JP2008543926A5 JP2008517630A JP2008517630A JP2008543926A5 JP 2008543926 A5 JP2008543926 A5 JP 2008543926A5 JP 2008517630 A JP2008517630 A JP 2008517630A JP 2008517630 A JP2008517630 A JP 2008517630A JP 2008543926 A5 JP2008543926 A5 JP 2008543926A5
Authority
JP
Japan
Prior art keywords
use according
activated protein
administered
human
inflammatory lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008517630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543926A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/002773 external-priority patent/WO2007012976A2/en
Publication of JP2008543926A publication Critical patent/JP2008543926A/ja
Publication of JP2008543926A5 publication Critical patent/JP2008543926A5/ja
Pending legal-status Critical Current

Links

JP2008517630A 2005-06-24 2006-06-23 呼吸器系に影響を及ぼす炎症状態における活性化プロテインｃの気道投与 Pending JP2008543926A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002773 WO2007012976A2 (en) 2005-06-24 2006-06-23 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013037700A Division JP2013151510A (ja) 2005-06-24 2013-02-27 呼吸器系に影響を及ぼす炎症状態における活性化プロテインｃの気道投与

Publications (2)

Publication Number Publication Date
JP2008543926A JP2008543926A (ja) 2008-12-04
JP2008543926A5 true JP2008543926A5 (https=) 2009-08-13

Family

ID=37570814

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008517630A Pending JP2008543926A (ja) 2005-06-24 2006-06-23 呼吸器系に影響を及ぼす炎症状態における活性化プロテインｃの気道投与
JP2008517629A Pending JP2008543925A (ja) 2005-06-24 2006-06-23 呼吸器系に影響を及ぼす炎症状態における組織因子系凝固インヒビターの気道投与
JP2013037700A Pending JP2013151510A (ja) 2005-06-24 2013-02-27 呼吸器系に影響を及ぼす炎症状態における活性化プロテインｃの気道投与

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008517629A Pending JP2008543925A (ja) 2005-06-24 2006-06-23 呼吸器系に影響を及ぼす炎症状態における組織因子系凝固インヒビターの気道投与
JP2013037700A Pending JP2013151510A (ja) 2005-06-24 2013-02-27 呼吸器系に影響を及ぼす炎症状態における活性化プロテインｃの気道投与

Country Status (14)

Country Link
US (3) US20100279925A1 (https=)
EP (3) EP1896059B1 (https=)
JP (3) JP2008543926A (https=)
KR (2) KR20080074085A (https=)
CN (2) CN101262880A (https=)
AU (2) AU2006260599A1 (https=)
BR (2) BRPI0611710A2 (https=)
CA (2) CA2612597C (https=)
DK (3) DK1898945T3 (https=)
IL (2) IL188220A0 (https=)
NO (2) NO20080434L (https=)
RU (2) RU2496515C2 (https=)
WO (3) WO2007012976A2 (https=)
ZA (2) ZA200800251B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101787B1 (en) * 2006-12-11 2013-09-18 Drugrecure ApS Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
PT3137102T (pt) * 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
WO2018053029A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
EP0946715B1 (en) * 1996-11-08 2006-03-29 Oklahoma Medical Research Foundation Use of a modified protein c
WO1998032459A1 (en) * 1997-01-29 1998-07-30 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU2002338487A1 (en) * 2001-05-02 2002-11-11 Novo Nordisk A/S Modified fvii in treatment of ards
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EP1446140A4 (en) * 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
KR100674315B1 (ko) * 2002-02-08 2007-01-24 에스케이 주식회사 가열로 튜브 세척제 및 세척방법
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
DE602004019761D1 (de) 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
DK1791555T3 (da) * 2004-09-10 2013-06-10 Pharmaorigin Aps Fremgangsmåde til behandling af lokal tracheal, bronchial eller alveolær blødning eller hæmoptyse
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Similar Documents

Publication Publication Date Title
Levy et al. High-flow oxygen therapy and other inhaled therapies in intensive care units
Alothman et al. Bronchial constriction and inhaled colistin in cystic fibrosis
US20180085462A1 (en) Topical use of levofloxacin for reducing lung inflammation
JP2010522212A5 (https=)
JP2010508365A5 (https=)
JP2012503668A5 (https=)
JP2011144201A5 (https=)
CN106535889A (zh) 用于治疗肺疾病的肥大细胞稳定剂
JP2007520508A5 (https=)
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
Siobal Aerosolized prostacyclins
RU2007107915A (ru) Лекарственные средства для лечения хронического респираторного заболевания
JP2008543926A5 (https=)
US20100285139A1 (en) Pharmaceutical composition for the prophylaxis and/or symptomatic treatment of cystic fibrosis
RU2012156256A (ru) Факторы трилистника (tff) для лечения хронических заболеваний легких
JP2008516991A5 (https=)
CN113546089A (zh) 1-乙基-3，7-二甲基黄嘌呤在制备治疗肺炎药物中的应用
Debnath et al. Status of inhalable antimicrobial agents for lung infection: progress and prospects
RU2008102655A (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
JP2011012060A5 (https=)
Stout et al. Local treatment of respiratory infections with antibiotics
JPWO2022096708A5 (https=)
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
US20220168297A1 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
JP2010189301A (ja) 新型インフルエンザ感染症に対する医薬組成物およびその利用